David Kerr

CBE FMedSci FRCP

Professor of Cancer Medicine

Consultant Physician

In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.

Key publications

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article

Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557

Recent publications

Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.
Journal article

Tanskanen T. et al, (2018), Int J Cancer, 142, 540 - 546
Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer.
Journal article

Hutchins GGA. et al, (2018), Histopathology, 72, 391 - 404
Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.
Journal article

May-Wilson S. et al, (2017), Eur J Cancer, 84, 228 - 238
Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer.
Journal article

Rodriguez-Broadbent H. et al, (2017), Int J Cancer, 140, 2701 - 2708
Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.
Journal article

Sveen A. et al, (2017), Genome Med, 9

More publications